NEW YORK (GenomeWeb News) – Invivoscribe Technologies today said that a German court has ruled in its favor in a patent dispute over FLT3 testing technology.

The San Diego-based firm said that the German District court in Munich found MLL Muenchner Leukaemielabor GmbH Laboratories guilty of infringing a patent held by Takara Bio and licensed exclusively to Invivoscribe. It also noted that the court declined to stay enforcement of its decision.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.